Rituximab bio-similar for the treatment of myasthenia gravis (adults)

Document first published:
Page updated:
Topic:
Publication type:

NHS England has concluded that there is sufficient evidence to support the routine commissioning of this treatment for patients who fulfil the criteria listed in this document.

Document

Rituximab bio-similar for the treatment of myasthenia gravis (adults)

Rituximab bio-similar for the treatment of myasthenia gravis (adults)

  • PDF
  • 167 KB
  • 12 pages

Summary

Updated 23 June 2026.